We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BOSTON SCIENTIFIC REPORTS FAULTY DEFIBRILLATORS; ANNOUNCES MOVE TOWARD GREATER TRANSPARENCY

BOSTON SCIENTIFIC REPORTS FAULTY DEFIBRILLATORS; ANNOUNCES MOVE TOWARD GREATER TRANSPARENCY

May 22, 2006

Boston Scientific has warned that some defibrillators produced by its recently acquired subsidiary Guidant may suddenly stop working due to a battery malfunction, adding that it is working to make its postmarket surveillance of device performance more transparent.

In a letter warning physicians about the problem, Boston Scientific said the issue is a faulty capacitor contained in the Vitality HE implantable cardioverter defibrillator (ICD) and the Contak Renewal 3 and 4 cardiac resynchronization therapy defibrillators (CRT-D). The capacitor problem was confirmed in 30 defibrillators removed from patients as of May 8 and is suspected in 46 devices that are still implanted in patients. There have been no deaths or injuries linked to the device failures, the company noted. The device malfunctioned in two patients who underwent successful replacement procedures.

Boston Scientific became aware of these specific device failures after it acquired Guidant in April, although Guidant has had a long-running stream of failures and recalls. In November 2005, the company established a panel of outside experts to recommend changes to its product development policies for cardiac devices. The review panel identified a progression of organizational lapses in which Guidant failed to adequately communicate to physicians the risk of its defibrillators short-circuiting, or "arcing" -- even after the company had learned of that risk.

Boston Scientific said in a May 10 regulatory filing it is battling at least 300 legal claims related to Guidant defibrillators that had potentially fatal flaws in battery components. ()a href="http://www.fdanews.com/ddl/33_21/" target=_blank>

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing